Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes

Data from a phase II trial of an investigational intravenous drug designed to block the formation of blood clots shows potential to reduce the risk of death, a second heart attack, or other coronary complications compared with the current standard of care in patients presenting with acute coronary syndromes (heart attacks or unstable angina).

Read the whole article on Physorg

More from Physorg